Why the study?
Stabilizing the cardiac myosin super-relaxed state using myosin inhibitors is an attractive therapeutic strategy for heart diseases like hypertrophic cardiomyopathy, prompting investigation of the structure-function relationships of mavacamten and para-nitroblebbistatin.
Mavacamten and para-nitroblebbistatin stabilize cardiac myosin in distinct structural and functional states, offering mechanistic insights into myosin inhibitors for hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Should not yet alter myosin-inhibitor selection in HCM; challenges the SRX-equals-closed-IHM assumption and leaves open class-effect interchangeability.
Gollapudi et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: